Abstract Body

ACTG study A5316 found that during contraceptive intravaginal ring (IVR) use over 3 weeks, efavirenz-based ART (EFV) significantly decreased both ethinyl estradiol (EE) and etonogestrel (ENG) plasma exposure, while atazanavir/ritonavir-based ART (ATV) decreased EE, yet increased ENG. We explored the role of the IVR on vaginal microbial communities and vaginal small chain fatty acids (SCFA) as well as the role of the vaginal microbes/SCFA on hormone concentrations.

Of the 74 participants (25 ART Naïve; 25 EFV, 24 ATV), 71 had 16S rRNA sequencing of the V4 region on vaginal swabs at weeks 0 (pre-IVR insertion), 1, 2, 3, and 4 (1 week post-IVR removal); and 73 had vaginal aspirate SCFAs measured by Metabolon® at weeks 0, 1 or 2, and 4. Sequences were filtered and taxa assigned using DADA2, species using SPINGO with SILVA database, and Lactobacillus using BLAST. Negative binomial and linear regression models identified differentially abundant microbiome and SCFA features, respectively. Spearman correlation assessed relationships between microbiome relative abundance and weekly EE/ENG concentrations.

At baseline, microbial communities of participants could be robustly classified as L. crispatus­-dominant (Community State Type (CST) I, n=8), L. gasseri-dominant (CST II, n=2), L. iners-dominant (CST III, n=20), or mixed anaerobic communities (CST IV, n=41). Start of IVR therapy was associated with an increased probability of transition into Lactobacillus-dominant community types (OR=3.39, CI=0.36-32.15), Fisher's exact test, p<0.001). ENG levels were negatively correlated with abundance of Prevotella timonensis. After IVR removal, an increased probability of transition into CST IV (OR=7.75, CI=1.56-38.49), p<0.001) was observed, with a decrease in lactic acid levels (p<0.001). Negative binomial modeling of the most abundant taxa between week 3 (during IVR use) and 4 (1 week after IVR removal) showed significant increases in Gardnerella vaginalis, unclassified Prevotella sp., and P. timonensis, and decreases in L. crispatus.

The shift in vaginal microbial communities from Lactobacillus-dominant types (CST I-III) to CST IV following removal of the ENG/EE IVR is concerning. Some women had a favorable response to the IVR, which may suggest this IVR is a therapeutic option for women with bacterial vaginosis. Further investigation is needed to fully assess interactions and safety of vaginal hormonal contraception in women with HIV-1.